Find Out If You Have a Case
Free, confidential review by Attorney Matthew T. Marin. Prefer to talk? Call (888) 348-2735.
Dupixent Lawsuit — Free, Confidential Case Review
Sézary syndrome after Dupixent? You may qualify.
Sézary syndrome is an aggressive form of CTCL and is on the qualifying list. A diagnosis like this deserves an answer — free and confidential.
ACTIVE LITIGATION — NO SETTLEMENT. MDL 3180 underway · filing deadlines vary by state.
Were you — or someone you love — diagnosed with CTCL or another T-cell lymphoma after taking Dupixent?
Check if my case qualifiesfree · confidential · takes 2 minutes
I’m not sure of my exact diagnosis →
No documents needed · confidential · an answer either way · no fee unless there is a recovery. Court costs and litigation expenses are advanced by counsel and repaid from the recovery. You are not responsible for court costs or litigation expenses if there is no recovery, unless a court directs otherwise. The attorney’s fee is a percentage of the gross recovery, calculated before expenses are deducted.
Or talk to a person now: (888) 348-2735 — answered 24/7
Stefanie A. Murphy & Matthew T. Marin
Partners
Every Dupixent inquiry gets a personal review — and an honest answer either way, free and without obligation.
Claims are brought against Sanofi and Regeneron, the makers of Dupixent — not against your doctor. Conversations are confidential. Some matters may be referred to other lawyers. No settlement has been reached, and most cases are in their earliest stages; every case must be proven on its own facts. Attorney Advertising.
Sézary syndrome is a rare form of cutaneous T-cell lymphoma in which abnormal T cells are present in the blood as well as the skin, which is why it is often called the leukemic form of CTCL. A SEER analysis in JAMA Oncology reported it at about 0.21 cases per million person-years. It usually appears as redness covering most of the body.
This page is about a lawsuit — it is not medical advice, and filing a claim does not require you to stop taking Dupixent. Decisions about your medication belong with you and your doctor.
Lawsuits consolidated in MDL 3180 (D.N.J.) allege that Dupixent (dupilumab) is associated with an increased risk of cutaneous T-cell lymphoma (CTCL) and that the manufacturers failed to warn about it. No court has ruled on these allegations, no settlement exists, and the litigation is in its earliest stages. Published studies report a statistical association — which the study authors themselves note does not establish causation — and the FDA has identified a potential safety signal it is still evaluating; Dupixent’s FDA label does not currently warn about lymphoma. Whether any individual has a claim depends on their medical records and the law of their state.
What is Sézary syndrome?
Sézary syndrome is a form of cutaneous T-cell lymphoma. What sets it apart from the other forms is where the abnormal cells are found: not only in the skin but circulating in the blood. That is why it is often described as the leukemic variant of CTCL. It tends to move faster than mycosis fungoides and to affect the whole body surface rather than a few areas.
How rare is Sézary syndrome?
The SEER population-data analysis published in JAMA Oncology in 2022 reported Sézary syndrome at about 0.21 cases per million person-years in the United States, set against 8.55 per million person-years for cutaneous T-cell lymphoma overall. In plain terms, it is one of the rarest diagnoses inside a group of diagnoses that is already rare. Most physicians will see very few in a career, and that is part of why it is so often reached late.
What does erythroderma actually feel like?
Erythroderma is the clinical term for redness and scaling across most of the body. What people describe is plainer than the word: red from head to foot, skin that burns and then will not hold heat, shedding that fills the bed and the shower drain, swelling in the hands and feet, and an itch that does not stop and does not answer to anything. Sleep goes first. It is one of the most physically punishing things a person can live with, and it has many causes, most of which are not lymphoma.
How is Sézary syndrome different from mycosis fungoides?
Both belong to the cutaneous T-cell lymphoma family, and the two names often appear in the same medical record. Mycosis fungoides usually starts as separate patches and thickened plaques and can stay that way for years. Sézary syndrome involves the blood, generally covers most of the skin surface, and is usually staged as advanced disease from the outset. Both appear on the qualifying list used for Dupixent claims.
How is Sézary syndrome diagnosed?
Diagnosis generally pairs a skin biopsy with blood testing, since the defining feature is abnormal T cells in the circulation. Laboratory work identifies which surface markers the cells carry and whether the T cells present look like copies of a single cell rather than a normal mixed population. Because erythroderma has many causes, people are often treated for severe eczema, psoriasis, or a drug reaction before the blood findings point somewhere else.
Why is Sézary syndrome so often reached late?
Rarity is part of it. So is overlap: a 2026 editorial in the American Journal of Clinical Dermatology describes “considerable clinical and histopathologic overlap between AD and early-stage MF, which may lead to initial misdiagnosis.” Someone with lifelong severe eczema who becomes red all over is, on the face of it, someone whose eczema got worse. Families often say afterward that they knew something had changed long before anyone named it. That instinct was not wrong, and the delay was not their fault.
Does Sézary syndrome qualify for the Dupixent lawsuit?
Sézary syndrome is named on the qualifying list this firm works from for the Dupixent lawsuit. The full set of qualifying subtypes runs to fourteen entries, and the page on who qualifies sets out the criteria in full.
- A Sézary syndrome diagnosis made after or during Dupixent use.
- No minimum length of Dupixent use is required.
- Claims may be brought on behalf of someone who has died, through their estate.
- A spouse, adult child, or personal representative can start the review.
Marin & Murphy Law Firm is currently accepting Dupixent CTCL cases. A review is confidential and carries no obligation.
Free Confidential Evaluation — No Fee Unless There Is a Recovery
Court costs and litigation expenses are advanced by counsel and repaid from the recovery. You are not responsible for court costs or litigation expenses if there is no recovery, unless a court directs otherwise. The attorney’s fee is a percentage of the gross recovery, calculated before expenses are deducted.
What else do people ask about Sézary syndrome?
What is Sézary syndrome?
Sézary syndrome is a form of cutaneous T-cell lymphoma in which the abnormal T cells are found in the blood as well as in the skin. It is often described as the leukemic form of CTCL for that reason, and it usually appears as widespread redness and intense itching rather than separate patches.
How is Sézary syndrome different from mycosis fungoides?
Both are forms of cutaneous T-cell lymphoma. Mycosis fungoides usually begins as separate patches and plaques on the skin. Sézary syndrome involves the blood as well as the skin and typically presents with redness covering most of the body. It is far less common and generally moves faster.
What does erythroderma mean?
Erythroderma is the clinical word for redness and scaling covering most of the body surface. People describe it as being red head to foot, burning or freezing constantly, shedding skin, and being unable to sleep. It has many possible causes, most of which are not lymphoma.
How rare is Sézary syndrome?
A SEER population-data analysis published in JAMA Oncology in 2022 reported Sézary syndrome at about 0.21 cases per million person-years in the United States, against 8.55 per million person-years for cutaneous T-cell lymphoma overall. It is one of the rarest diagnoses in an already rare group.
How is Sézary syndrome diagnosed?
Diagnosis generally combines a skin biopsy with blood testing, because the defining feature is abnormal T cells circulating in the blood. Laboratory work identifies which markers those cells carry and whether they appear to be copies of a single cell. Your treating physicians are the only people who can make that call.
Does Sézary syndrome qualify for the Dupixent lawsuit?
Sézary syndrome appears by name on the list of qualifying lymphoma diagnoses this firm works from, where the diagnosis was made after or during Dupixent use. Whether any individual has a claim depends on their medical records and the law of their state.
Can a claim be reviewed if the person diagnosed has died?
Yes. Claims may be brought on behalf of someone who has died, through their estate, and a spouse, adult child, or personal representative can start that conversation. The documents that matter are usually medical records, pharmacy records, and estate paperwork.
Do I have to stop Dupixent to talk to a lawyer?
No. Asking a firm to review records does not require anyone to change or stop a medication, and this firm does not give medical advice. Decisions about Dupixent belong with the patient and the prescribing physician. There is no fee unless there is a recovery.
Free Confidential Evaluation — No Fee Unless There Is a Recovery
Court costs and litigation expenses are advanced by counsel and repaid from the recovery. You are not responsible for court costs or litigation expenses if there is no recovery, unless a court directs otherwise. The attorney’s fee is a percentage of the gross recovery, calculated before expenses are deducted.
Sources
- “Incidence Trends of Primary Cutaneous T-Cell Lymphoma in the US From 2000 to 2018: A SEER Population Data Analysis,” JAMA Oncology 2022;8(11):1690–1692 — jamanetwork.com
- “Dupilumab and Cutaneous T-Cell Lymphoma: A Call for Vigilance, Not Alarm,” American Journal of Clinical Dermatology 2026;27:5–7 — link.springer.com
- Qualifying-diagnosis list per the referring counsel intake criteria dated February 6, 2026 (on file with Marin & Murphy Law Firm).
- FDA, “October–December 2024 Potential Signals of Serious Risks Identified from FAERS” — fda.gov
- National Cancer Institute, Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®), Patient Version — cancer.gov
Matthew T. Marin — RI, CT, MA, SC, U.S.D.C. D.R.I. · Stefanie A. Murphy — RI, CT, MA, U.S.D.C. D.R.I./D.Conn./D.Mass.
Attorney Advertising.
Attorney Advertising. This page is for general information and is not legal advice; reading it does not create an attorney-client relationship, and no attorney-client relationship is formed until a written engagement agreement is signed. Marin & Murphy Law Firm attorneys are licensed in Rhode Island, Connecticut, Massachusetts, and South Carolina; the firm’s mass-tort practice is directed from its Charleston, South Carolina office. Responsible attorney: Matthew T. Marin, 997 Morrison Drive, Suite 200, Charleston, SC 29403. Cases may be handled together with co-counsel; whether a claim is accepted is determined after review. No representation is made that the quality of legal services is greater than that of other lawyers. Prior results do not guarantee a similar outcome; every case depends on its own facts.